Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA introduces human tissue task force

This article was originally published in The Gray Sheet

Executive Summary

The group is charged to assess the effectiveness of new tissue regulations that took effect in May 2005, focusing on recent findings that some tissue recovery establishments do not follow federal requirements, the agency said Aug. 30 (1"The Gray Sheet" Nov. 22, 2004, p. 6). "The creation of this task force is part of the agency's overall plan to ensure that all human cells and tissues are as safe as possible," said Jesse Goodman, MD, director of the Center for Biologics Evaluation & Research. On Aug. 18, FDA ordered Donor Referral Services to cease manufacturing of human cells, tissues and cellular and tissue-based products and to retain all such products. An FDA inspection of the Raleigh, N.C., operation found "serious" violations of manufacturing procedures and recordkeeping requirements...

You may also be interested in...



FDA tissue inspections

An inspection "blitz" on companies that recover human tissues for transplantation found no significant compliance problems, FDA's Human Tissue Task Force 1reports June 12. FDA inspected 153 U.S. tissue recovery firms from October 2006 through March 2007, and while some deviations from FDA's tissue regulations were found, there were no major deficiencies that could put patients at risk for disease transmission, the report says. The task force, which called for the inspections after serious violations were discovered at two tissue recovery firms last year, recommends that human tissue companies performing the highest-risk manufacturing steps be inspected every two years, and all others every three years (2"The Gray Sheet" Sept. 4, 2006, In Brief). FDA plans 484 tissue-facility inspections in fiscal 2007. More than 2,000 human cell and tissue establishments are registered with FDA, with 1.5 million musculoskeletal tissue transplants performed each year...

FDA Completes “Risk-Based” Reg Trilogy With Good Tissue Practices

Manufacturers of tissue products have until May 25 to implement a comprehensive tissue tracking system under the 1Good Tissue Practice (GTP) regulations finalized Nov. 18

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel